<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676607</url>
  </required_header>
  <id_info>
    <org_study_id>mCRPC-IIT-SHR7390</org_study_id>
    <nct_id>NCT04676607</nct_id>
  </id_info>
  <brief_title>SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer</brief_title>
  <official_title>SHR7390 in the Treatment of Metastatic Hormone-Resistant Prostate Cancer That Failed Previous Docetaxel and New Endocrine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to prospectively assess the safety and efficiency of SHR7390 in metastatic&#xD;
      castration-resistant prostate cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of patients with measureable disease at baseline who achieved a complete or partial response in their soft tissue disease using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AE</measure>
    <time_frame>2 years</time_frame>
    <description>The type, frequency, severity, timing, seriousness, and relationship to study therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA response rate</measure>
    <time_frame>2 years</time_frame>
    <description>After the continuous therapy from randomisation to the end of the 12 weeks, the percentage of patients whose levels of PSA decreased by more than 50% compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to prostate specific antigen (PSA) progression</measure>
    <time_frame>2 years</time_frame>
    <description>Time from randomisation to the first time of PSA progression according to the criterion of PCGW3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Progression Free Survival(rPFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Time from randomisation to radiologically confirmed progressive disease or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>2 years</time_frame>
    <description>Time from randomisation to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR</measure>
    <time_frame>2 years</time_frame>
    <description>Time from radiologically confirmed reponse to radiologically confirmed progressive disease or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to skeletal-related events</measure>
    <time_frame>2 years</time_frame>
    <description>Time from randomisation to the first occurrence of a skeletal-related event. The skeletal-related event is defined as the occurrence of either pathological or clinical fracture, spinal cord compression, bone-related radiotherapy or surgery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR7390</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR7390</intervention_name>
    <description>SHR7390</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18-75 years，male&#xD;
&#xD;
          -  ECOG PS：0-1&#xD;
&#xD;
          -  Life expectancy of more than 6 months&#xD;
&#xD;
          -  After surgery or drug castration, testosterone level was &lt; 50 ng / dl. For subject&#xD;
             receiving LHRH agonist / antagonist therapy (patients without orchiectomy), the&#xD;
             treatment must start at least 4 weeks before the first day of cycle 1 and must be&#xD;
             continued throughout the study&#xD;
&#xD;
          -  Failure (radiological or PSA progression) or intolerance of at least one but not more&#xD;
             than two taxanes based chemotherapy regimens and novel endocrine therapy (at least one&#xD;
             of enzalutamide, apartamide, abitelone or shr3680). If docetaxel regimen used more&#xD;
             than once, count as one regimen&#xD;
&#xD;
          -  Disease progressed within 6 months prior to inclusion in the study. Disease&#xD;
             progression defined as the occurrence of one or more of the following three items at&#xD;
             the same time of castration：&#xD;
&#xD;
             ① PSA progression，defined as at least twice increases in PSA level (interval time ≥ 1&#xD;
             week, and PSA level at screening should be ≥ 2ng / ml)&#xD;
&#xD;
             ②Disease progression as defined in RECIST 1.1&#xD;
&#xD;
             ③Bone disease progression defined by PCWG3，more than 2 new lesions in bone scan&#xD;
&#xD;
          -  Metastatic lesions with radiologica evidence， measurable non-bone target lesions&#xD;
&#xD;
          -  Adequate hepatic, renal, heart, and hematologic functions (no blood transfusion or&#xD;
             hematopoietic growth factor treatment within 2 weeks before blood routine&#xD;
             screening)：platelets&gt;80×10^9/L，neutrophil&gt;1.5×10^9/L, Hb≥90 g/L,total&#xD;
             bilirubin≤1.5×limit of normal(ULN), ALT and AST ≤2.5×ULN（≤5×ULN with liver&#xD;
             metastasis），blood urea nitrogen and creatinine≤1.5×ULN&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedure&#xD;
&#xD;
          -  Willing to participate in this clinical trial, understand the research procedures and&#xD;
             have signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with MEK inhibitors，including trametinib&#xD;
&#xD;
          -  Washout period from the end of any previous anti-tumor treatment (including&#xD;
             radiotherapy, chemotherapy, surgery, molecular targeted therapy, immunotherapy,&#xD;
             androgen receptor inhibitors, CYP-17 inhibitors, 5 α-reductase inhibitors, estrogen,&#xD;
             progesterone drugs, etc) to the first administration of the study drug less than 1&#xD;
             week (bicalutamide elution period &lt; 2 weeks)&#xD;
&#xD;
          -  Plant drugs (e.g. Saw Palmetto) or steroids that may reduce PSA levels within 4 weeks,&#xD;
             or planned to be used during the trial period (except for temporary steroid drugs for&#xD;
             preventing or treating allergies)&#xD;
&#xD;
          -  Plan to receive any other anti-tumor treatment during this trial&#xD;
&#xD;
          -  Last drug administration from other clinical trials within 4 weeks&#xD;
&#xD;
          -  Radiological confirmed tumor foci in the brain&#xD;
&#xD;
          -  Severe bone injury caused by tumor bone metastasis judged by researchers, including&#xD;
             severe bone pain with poor control, pathological fracture of important parts and&#xD;
             spinal cord compression occurred or expected to occur in recent 6 months&#xD;
&#xD;
          -  History of epilepsy, or the disease that can induce epilepsy within 12 months&#xD;
             (including the history of transient ischemic attack, cerebral apoplexy (except for&#xD;
             cerebral ischemic foci simply found by imaging examination), brain trauma with&#xD;
             disturbance of consciousness and hospitalization）&#xD;
&#xD;
          -  Hypotension (systolic blood pressure &lt; 86mmhg) or uncontrollable hypertension&#xD;
             (systolic blood pressure ≥ 150mmhg or diastolic blood pressure ≥ 100mmhg) within 30&#xD;
             days. The blood pressure results were the average value of three consecutive&#xD;
             measurements with an interval of more than 2 minutes&#xD;
&#xD;
          -  Active heart disease including severe/unstable angina pectoris, myocardial infarction,&#xD;
             symptomatic congestive heart failure, and ventricular arrhythmias requiring drug&#xD;
             treatment within 6 months&#xD;
&#xD;
          -  Inability to swallow, chronic diarrhea and intestinal obstruction, or other factors&#xD;
             affecting drug administration and absorption&#xD;
&#xD;
          -  History of retinopathy confirmed by ophthalmic examination or neurosensory retinal&#xD;
             detachment. Risk factors such as retinal vein thrombosis / occlusion (RVO), central&#xD;
             serous retinopathy (CSR) or neovascular macular degeneration&#xD;
&#xD;
          -  IOP &gt; 21mmhg or diagnosed with glaucoma within 4 weeks&#xD;
&#xD;
          -  Active HBV or HCV infection (HBV copies ≥ 10^4 copies / ml, HCV copies ≥ 10^3&#xD;
             copies/ml)&#xD;
&#xD;
          -  History of immunodeficiency (including HIV positive, other acquired and congenital&#xD;
             immunodeficiency diseases) or organ transplantation history&#xD;
&#xD;
          -  Not willing to take effective contraceptive measures during the whole study period and&#xD;
             within 6 months after the last administration&#xD;
&#xD;
          -  Any accompanying diseases (such as poorly controlled hypertension, severe diabetes,&#xD;
             thyroid disease and psychosis) that seriously endanger the safety of patients or&#xD;
             affect the patients to complete the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongqian Guo</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Urology, Drum Tower Hospital, Medical School of Nanjing University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongqian Guo, Phd</last_name>
    <phone>8613605171690</phone>
    <email>dr.ghq@nju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hongqian Guo</last_name>
    <phone>8613605171690</phone>
    <email>dr.ghq@nju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Hongqian Guo</investigator_full_name>
    <investigator_title>Executive officer of Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

